[go: up one dir, main page]

WO2025175093A1 - Système et procédé de détermination d'accumulation de dose et de génération de profil de patient - Google Patents

Système et procédé de détermination d'accumulation de dose et de génération de profil de patient

Info

Publication number
WO2025175093A1
WO2025175093A1 PCT/US2025/015919 US2025015919W WO2025175093A1 WO 2025175093 A1 WO2025175093 A1 WO 2025175093A1 US 2025015919 W US2025015919 W US 2025015919W WO 2025175093 A1 WO2025175093 A1 WO 2025175093A1
Authority
WO
WIPO (PCT)
Prior art keywords
dose
patient
location
treatment session
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/015919
Other languages
English (en)
Inventor
Jacob G. SCOTT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cleveland Clinic Foundation
Original Assignee
Cleveland Clinic Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cleveland Clinic Foundation filed Critical Cleveland Clinic Foundation
Publication of WO2025175093A1 publication Critical patent/WO2025175093A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/103—Treatment planning systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/40—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
    • G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
    • G16H40/67—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for remote operation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/70—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/103—Treatment planning systems
    • A61N2005/1041—Treatment planning systems using a library of previously administered radiation treatment applied to other patients

Definitions

  • the present disclosure relates to dose planning and/or administration.
  • Radiation therapy may use controlled doses of radiation to a tumor. Dosing may be calculated based upon tumor type, size, location and/or patient health. Over-dosing and/or under-dosing may impact efficacy and/or side effects, making accurate planning and delivery critical for positive treatment outcomes.
  • records of treatment sessions of a patient may be collected.
  • Each of the records may be indicative of a time of a treatment session, a dose parameter of a dose administered to a location of a body of the patient in the treatment session, and/or the location of the body of the patient.
  • a patient profile including dose records mapped to locations of the body may be generated based upon times, dose parameters, and locations indicated by the records.
  • the patient profile may be provided to a device for display.
  • FIG. 1 is an illustration of a scenario involving various examples of networks that may connect servers and clients.
  • FIG. 2 is an illustration of a scenario involving an example configuration of a server that may utilize and/or implement at least a portion of the techniques presented herein.
  • FIG. 3 is an illustration of a scenario involving an example configuration of a client that may utilize and/or implement at least a portion of the techniques presented herein.
  • FIG. 4 illustrates a flow chart illustrating an example method, in accordance with some embodiments.
  • Fig. 5C illustrates a client device displaying a patient profile interface, in accordance with some embodiments.
  • FIG. 7 is an illustration of a scenario featuring an example non- transitory machine readable medium in accordance with one or more of the provisions set forth herein.
  • one or more client devices 110 may communicate with the service 102 by connecting to the wide area network 108 via a wireless local area network 106 provided by a location such as the user’s home or workplace.
  • the wireless local area network 106 may, for example, be a WiFi (Institute of Electrical and Electronics Engineers (IEEE) Standard 802.11 ) network or a Bluetooth (IEEE Standard 802.15.1 ) personal area network.
  • the servers 104 and the client devices 110 may communicate over various types of networks.
  • Exemplary types of networks that may be accessed by the servers 104 and/or client devices 110 include mass storage, such as network attached storage (NAS), a storage area network (SAN), or other forms of computer or machine readable media.
  • mass storage such as network attached storage (NAS), a storage area network (SAN), or other forms of computer or machine readable media.
  • the servers 104 of the service 102 may be interconnected directly, or through one or more other networking devices, such as routers, switches, and/or repeaters.
  • the servers 104 may utilize a variety of physical networking protocols, such as Ethernet and/or Fiber Channel, and/or logical networking protocols, such as variants of an Internet Protocol (IP), a Transmission Control Protocol (TCP), and/or a User Datagram Protocol (UDP).
  • IP Internet Protocol
  • TCP Transmission Control Protocol
  • UDP User Datagram Protocol
  • the servers 104 of the service 102 may be internally connected via a local area network 106.
  • the local area network 106 may be organized according to one or more network architectures, such as server/client, peer- to-peer, and/or mesh architectures, and/or a variety of roles, such as administrative servers, authentication servers, security monitor servers, data stores for objects such as files and databases, business logic servers, time synchronization servers, and/or front-end servers providing a user-facing interface for the service 102.
  • network architectures such as server/client, peer- to-peer, and/or mesh architectures, and/or a variety of roles, such as administrative servers, authentication servers, security monitor servers, data stores for objects such as files and databases, business logic servers, time synchronization servers, and/or front-end servers providing a user-facing interface for the service 102.
  • the local area network 106 may be a wired network where network adapters on the respective servers 104 are interconnected via cables (e.g., coaxial and/or fiber optic cabling), and may be connected in various topologies (e.g., buses, token rings, meshes, and/or trees).
  • the local area network 106 may include, e.g., analog telephone lines, such as a twisted wire pair, a coaxial cable, full or fractional digital lines including T1 , T2, T3, or T4 type lines, Integrated Services Digital Networks (ISDNs), Digital Subscriber Lines (DSLs), wireless links including satellite links, or other communication links or channels, such as may be known to those skilled in the art.
  • ISDNs Integrated Services Digital Networks
  • DSLs Digital Subscriber Lines
  • the local area network 106 may comprise one or more sub-networks, such as may employ differing architectures, may be compliant or compatible with differing protocols and/or may interoperate within the local area network 106. Additionally, a variety of local area networks 106 may be interconnected; e.g., a router may provide a link between otherwise separate and independent local area networks 106.
  • the server 104 may comprise a variety of peripheral components, such as a wired and/or wireless network adapter 214 connectible to a local area network and/or wide area network; one or more storage components 216, such as a hard disk drive, a solid-state storage device (SSD), a flash memory device, and/or a magnetic and/or optical disk reader.
  • peripheral components such as a wired and/or wireless network adapter 214 connectible to a local area network and/or wide area network
  • storage components 216 such as a hard disk drive, a solid-state storage device (SSD), a flash memory device, and/or a magnetic and/or optical disk reader.
  • the server 104 may comprise memory 202 storing various forms of applications, such as an operating system 204; one or more server applications 206, such as a hypertext transport protocol (HTTP) server, a file transfer protocol (FTP) server, or a simple mail transport protocol (SMTP) server; and/or various forms of data, such as a database 208 or a file system.
  • server applications 206 such as a hypertext transport protocol (HTTP) server, a file transfer protocol (FTP) server, or a simple mail transport protocol (SMTP) server
  • HTTP hypertext transport protocol
  • FTP file transfer protocol
  • SMTP simple mail transport protocol
  • the server 104 may comprise one or more processors 210 that process instructions.
  • the one or more processors 210 may optionally include a plurality of cores; one or more coprocessors, such as a mathematics coprocessor or an integrated graphical processing unit (GPU); and/or one or more layers of local cache memory.
  • the server 104 may comprise a mainboard featuring one or more communication buses 212 that interconnect the processor 210, the memory 202, and various peripherals, using a variety of bus technologies, such as a variant of a serial or parallel AT Attachment (ATA) bus protocol; a Uniform Serial Bus (USB) protocol; and/or Small Computer System Interface (SCI) bus protocol.
  • a communication bus 212 may interconnect the server 104 with at least one other server.
  • the server 104 may operate in various physical enclosures, such as a desktop or tower, and/or may be integrated with a display as an “all-in- one” device.
  • the server 104 may be mounted horizontally and/or in a cabinet or rack, and/or may simply comprise an interconnected set of components.
  • the server 104 may include one or more other components that are not shown in the schematic diagram 200 of Fig. 2, such as a display; a display adapter, such as a graphical processing unit (GPU); input peripherals, such as a keyboard and/or mouse; and a flash memory device that may store a basic input/output system (BIOS) routine that facilitates booting the server 104 to a state of readiness.
  • a display adapter such as a graphical processing unit (GPU)
  • input peripherals such as a keyboard and/or mouse
  • BIOS basic input/output system
  • a plurality of such servers 104 may be configured and/or adapted to utilize at least a portion of the techniques presented herein.
  • FIG. 3 presents a schematic architecture diagram 300 of a client device 1 10 whereupon at least a portion of the techniques presented herein may be implemented.
  • client device 110 may vary widely in configuration or capabilities, in order to provide a variety of functionality to a user such as the user 112.
  • the client device 110 may comprise memory 301 storing various forms of applications, such as an operating system 303; one or more user applications 302, such as document applications, media applications, file and/or data access applications, communication applications such as web browsers and/or email clients, utilities, and/or games; and/or drivers for various peripherals.
  • applications such as an operating system 303
  • user applications 302 such as document applications, media applications, file and/or data access applications, communication applications such as web browsers and/or email clients, utilities, and/or games; and/or drivers for various peripherals.
  • a software application on a client device 110 e.g., an instant messenger and/or electronic mail application
  • descriptive content in the form of signals or stored physical states within memory e.g., an email address, instant messenger identifier, phone number, postal address, message content, date, and/or time
  • descriptive content may be stored, typically along with contextual content.
  • the source of an email address e.g., a communication received from another user via an instant messenger application
  • Contextual content may identify circumstances surrounding receipt of an email address (e.g., the date or time that the email address was received), and may be associated with descriptive content.
  • Contextual content may, for example, be used to subsequently search for associated descriptive content. For example, a search for email addresses received from specific individuals, received via an instant messenger application or at a given date or time, may be initiated.
  • the client device 110 may comprise one or more processors 310 that process instructions.
  • the one or more processors 310 may optionally include a plurality of cores; one or more coprocessors, such as a mathematics coprocessor or an integrated graphical processing unit (GPU); and/or one or more layers of local cache memory.
  • coprocessors such as a mathematics coprocessor or an integrated graphical processing unit (GPU)
  • GPU integrated graphical processing unit
  • the client device 110 may comprise a dedicated and/or shared power supply 318 that supplies and/or regulates power for other components, and/or a battery 304 that stores power for use while the client device 110 is not connected to a power source via the power supply 318.
  • the client device 110 may provide power to and/or receive power from other client devices.
  • the client device 110 may comprise a variety of peripheral components, such as a wired and/or wireless network adapter 306 connectible to a local area network and/or wide area network; one or more output components, such as a display 308 coupled with a display adapter (optionally including a graphical processing unit (GPU)), a sound adapter coupled with a speaker, and/or a printer; input devices for receiving input from the user, such as a keyboard 311 , a mouse, a microphone, a camera, and/or a touch-sensitive component of the display 308; and/or environmental sensors, such as a global positioning system (GPS) receiver 319 that detects the location, velocity, and/or acceleration of the client device 110, a compass, accelerometer, and/or gyroscope that detects a physical orientation of the client device 110.
  • GPS global positioning system
  • the client device 110 may comprise a mainboard featuring one or more communication buses 312 that interconnect the processor 310, the memory 301 , and various peripherals, using a variety of bus technologies, such as a variant of a serial or parallel AT Attachment (ATA) bus protocol; the Uniform Serial Bus (USB) protocol; and/or the Small Computer System Interface (SCI) bus protocol.
  • ATA serial or parallel AT Attachment
  • USB Uniform Serial Bus
  • SCI Small Computer System Interface
  • the client device 110 may include one or more other components that are not shown in the schematic architecture diagram 300 of Fig.
  • the client device 110 may include a climate control unit that regulates climate properties, such as temperature, humidity, and airflow.
  • climate control unit that regulates climate properties, such as temperature, humidity, and airflow.
  • the client device 110 may include one or more servers that may locally serve the client device 110 and/or other client devices of the user 112 and/or other individuals.
  • a locally installed webserver may provide web content in response to locally submitted web requests.
  • client devices 110 may be configured and/or adapted to utilize at least a portion of the techniques presented herein.
  • the client device 110 may serve the user in a variety of roles, such as a workstation, kiosk, media player, gaming device, and/or appliance.
  • the client device 110 may therefore be provided in a variety of form factors, such as a desktop or tower workstation; an “all-in-one” device integrated with a display 308; a laptop, tablet, convertible tablet, or palmtop device; a wearable device mountable in a headset, eyeglass, earpiece, and/or wristwatch, and/or integrated with an article of clothing; and/or a component of a piece of furniture, such as a tabletop, and/or of another device, such as a vehicle or residence.
  • RT radiation therapy
  • clinicians may need to decide how to treat metachronous lesions that neighbor previously irradiated areas of the body, which may require striking a balance between the therapeutic effect of a local therapy, such as stereotactic body radiation therapy (SBRT), and its potential toxicity to the tissue.
  • SBRT stereotactic body radiation therapy
  • care providers need a way to rigorously and reliably account for dose accumulations over multiple courses of radiation, and to reproducibly consider normal tissue recovery.
  • automated approaches to determining temporally corrected dose accumulation levels and/or generating patient profiles are provided herein.
  • records of treatment sessions of a patient may be collected from one or more sources.
  • Each of the records may be indicative of a time of a treatment session, a dose parameter of a dose administered to the patient in the treatment session, and/or a location to which the dose was administered.
  • a patient profile including dose records mapped to locations of the body may be generated based upon times, dose parameters, and locations indicated by the records.
  • the patient profile may be indicative of temporally corrected dose accumulation levels that account for human tissue recovery over time.
  • the patient profile may provide a healthcare professional with a visual and/or comprehensive profile of the patient’s radiation exposure.
  • the healthcare professional may have a more accurate understanding of the patient’s radiation exposure, such as due, at least in part, to the system accounting for human tissue recovery in determining the dose accumulation levels of the patient profile.
  • FIG. 5A illustrates the records 502 being collected by a patient profile generation module 506.
  • the records 502 may be collected from one or more sources, such as at least one of one or more medical record databases, dose administration equipment, a dosimeter, a user interface presented to a user (e.g., a healthcare professional) that uses the user interface to manually enter one or more parameters (e.g., patient information, dose information, etc.) associated with a treatment session.
  • sources such as at least one of one or more medical record databases, dose administration equipment, a dosimeter, a user interface presented to a user (e.g., a healthcare professional) that uses the user interface to manually enter one or more parameters (e.g., patient information, dose information, etc.) associated with a treatment session.
  • parameters e.g., patient information, dose information, etc.
  • one or more of the records 502 may be determined based upon a first electronic health record (EHR) associated with the first patient.
  • EHR electronic health record
  • an image analysis tool may scan (using artificial intelligence, for example) the first EHR to determine treatment information associated with one or more of the treatment sessions of the first patient, and/or may generate one or more of the records 502 based upon the treatment information.
  • the one or more of the records 502 may be determined based upon treatment information sets indicative of details of treatment sessions of the first patient performed at one or more treatment centers.
  • each of the records 502 may be indicative of one or more parameters associated with a treatment session.
  • the records 502 may comprise at least one of a first record 504 associated with a first treatment session of the first patient, a second record associated with a second treatment session of the first patient, etc.
  • the first record 504 may be indicative of a time of the first treatment session, a dose parameter of a dose administered to a location of a body of the first patient in the first treatment session, a dose location indicative of the location, a dose volume of the dose, a patient outcomes information set associated with the first patient and/or the first treatment session, and/or other information.
  • the dose parameter of the first treatment session may be indicative of absorbed (and/or delivered) dose (e.g., an amount of radiation absorbed by and/or delivered to the body in the first treatment session).
  • the dose parameter of the first treatment session may be indicative of absorbed (and/or delivered) dose per unit of weight and/or volume (e.g., an amount of radiation absorbed by and/or delivered to the body in the first treatment session per kilogram of tissue of the body).
  • the dose parameter may be determined based upon information reported by a healthcare professional (via a user interface, for example) and/or based upon one or more measurements recorded by a dosimeter configured to measure administration of the dose of the first treatment session.
  • the dose location is indicative of a region (e.g., a three-dimensional region) and/or a location point of the body to which the dose is absorbed by (and/or delivered to).
  • the dose location is indicative of one or more coordinates (e.g., three-dimensional coordinates) identifying the region and/or the location point of the body.
  • the dose volume is indicative of a volume of the region of the body.
  • the patient outcomes information set is indicative of one or more symptoms of the first patient, one or more side effects of the first patient, an intensity of side effects of the first patient (e.g., an intensity with which the dose and/or prior doses impacts the first patient), one or more toxicity grades associated with one or more locations of the body of the first patient (e.g., gastrointestinal toxicity grade, lung toxicity grade, etc.), etc.
  • at least a portion of the patient outcomes information set may be determined based upon information reported by the first patient (during the first treatment session, for example) and/or entered by a healthcare professional via a user interface (e.g., the first patient may be asked questions about symptoms, side effects, etc.
  • the patient outcomes information set may be generated based upon answers by the first patient to the questions).
  • at least some of the patient outcomes information set may be determined based upon patient-reported outcomes data (and/or healthcare professional-reported outcomes data, such as physician-reported outcomes data) from an outcomes data store (e.g., a patient and/or physician reported outcomes database).
  • the first treatment session (and/or other treatment sessions associated with other records of the records 502) may comprise a radiation therapy treatment session (e.g., SBRT treatment session and/or other type of radiation therapy treatment session), and/or the dose parameter may be indicative of an amount of radiation absorbed by and/or delivered to the body in the first treatment session.
  • a radiation therapy treatment session e.g., SBRT treatment session and/or other type of radiation therapy treatment session
  • the dose parameter may be indicative of an amount of radiation absorbed by and/or delivered to the body in the first treatment session.
  • the radiation therapy treatment session may be performed for one or more applications, such as a curative cancer application (e.g., to eliminate cancer of the first patient), a non-curative cancer application (e.g., the radiation therapy session may be part of at least one of palliative radiation therapy to relieve symptoms and/or improve quality of life, adjuvant therapy, neoadjuvant radiation therapy to shrink tumors, etc.), an autoimmune disorder application (e.g., to treat an autoimmune disorder of the first patient), and/or one or more other applications.
  • a curative cancer application e.g., to eliminate cancer of the first patient
  • a non-curative cancer application e.g., the radiation therapy session may be part of at least one of palliative radiation therapy to relieve symptoms and/or improve quality of life, adjuvant therapy, neoadjuvant radiation therapy to shrink tumors, etc.
  • an autoimmune disorder application e.g., to treat an autoimmune disorder of the first patient
  • the radiation therapy treatment session may be performed to treat keloids, Trigeminal Neuralgia, Arteriovenous Malformations (AVMs), Thyroid Eye Disease, Heterotopic Ossification (HO), and/or one or more other conditions.
  • the first treatment session (and/or other treatment sessions associated with other records of the records 502) may comprise a chemotherapy treatment session, and/or the dose parameter may be indicative of a dose of a chemical drug delivered (e.g., by at least one of oral chemotherapy, intravenous injection, etc.) to the first patient in the chemotherapy treatment session.
  • the chemotherapy treatment session may be performed for one or more applications, such as a curative cancer application (e.g., to eliminate cancer of the first patient), a non-curative cancer application, and/or one or more other applications.
  • the first treatment session (and/or other treatment sessions associated with other records of the records 502) may comprise a hyperthermia treatment session, and/or the dose parameter may be indicative of a temperature of a heating cycle of the hyperthermia treatment session, a duration of the heating cycle, and/or a number of cycles of the hyperthermia treatment session.
  • the dose location may correspond to tissue (e.g., abnormal and/or diseased tissue) of the body that is subjected to an increase in temperature during the hyperthermia treatment session (to kill cancer cells and/or increase a sensitivity of cancer cells to one or more other treatments, for example).
  • the hyperthermia treatment session may be performed for one or more applications, such as a curative cancer application, a non-curative cancer application, and/or one or more other applications.
  • the first treatment session (and/or other treatment sessions associated with other records of the records 502) may comprise a radiofrequency ablation (RFA) treatment session, and/or the dose parameter may be indicative of a temperature, an intensity and/or a frequency of radiofrequency waves generated by the RFA treatment session to heat tissue of the body (to destroy and/or shrink the tissue, for example) and/or a duration with which the heat generated by the radiofrequency waves is applied to the tissue.
  • RFA radiofrequency ablation
  • the dose location may correspond to tissue (e.g., abnormal and/or diseased tissue) of the body that is subjected to the heat applied by the RFA treatment session.
  • the RFA treatment session may be performed for one or more applications, such as a curative cancer application, a non-curative cancer application, and/or one or more other applications.
  • a first patient profile 508 may be generated based upon times, dose parameters, and/or locations indicated by the records 502.
  • Fig. 5A illustrates the first patient profile 508 being generated by the patient profile generation module 506.
  • the first patient profile 508 may comprise dose records mapped to locations of the body of the first patient.
  • each dose record of one, some and/or all of the dose records is indicative of historical dose information associated with a corresponding location of the body, dose accumulation information associated with the corresponding location of the body, dose suggestion information associated with the corresponding location of the body and/or patient outcomes information associated with the corresponding location of the body.
  • the historical dose information may be indicative of one or more times of one or more doses administered to the corresponding location of the body and/or one or more dose parameters of the one or more doses.
  • the dose accumulation information may be indicative of a dose accumulation level (e.g., a temporally corrected dose accumulation level) at the corresponding location of the body.
  • the dose suggestion information may be indicative of a dose suggestion associated with the corresponding location of the body.
  • the patient outcomes information may be indicative of one or more symptoms associated with the corresponding location of the body (reported by the first patient and/or a healthcare professional, for example), one or more side effects associated with the corresponding location (reported by the first patient and/or a healthcare professional, for example), an intensity of the one or more side effects, one or more toxicity grades associated with the corresponding location (reported by the first patient and/or a healthcare professional, for example), and/or other information associated with the corresponding location.
  • the dose records of the first patient profile 508 may comprise a first dose record associated with a first location of the body of the first patient, a second dose record associated with a second location of the body and/or other dose records associated with other locations of the body.
  • the first dose record may be indicative of first historical dose information, first dose accumulation information associated with the first location, first dose suggestion information associated with the first location and/or first patient outcomes information associated with the first location.
  • the first historical dose information may be indicative of one or more times of one or more first doses administered to the first location of the body and/or one or more dose parameters of the one or more first doses.
  • the first dose accumulation information may be indicative of a first dose accumulation level (e.g., a temporally corrected dose accumulation level) at the first location of the body.
  • the first patient outcomes information may be indicative of one or more symptoms associated with the first location, one or more times that the one or more symptoms were experienced and/or reported, one or more side effects associated with the first location, one or more times that the one or more side effects were experienced and/or reported, an intensity of the one or more side effects, one or more toxicity grades associated with the first location, one or more times that the one or more toxicity grades were experienced and/or reported, and/or other information associated with the first location.
  • the first patient outcomes information may be determined based upon one or more patient outcomes information sets (e.g., the patient outcomes information set of the first record 504) associated with the first location (e.g., the one or more patient outcome information sets may be retrieved from the records 502 and/or the outcomes data store).
  • one or more patient outcomes information sets e.g., the patient outcomes information set of the first record 504 associated with the first location (e.g., the one or more patient outcome information sets may be retrieved from the records 502 and/or the outcomes data store).
  • the second dose record may be indicative of second historical dose information, second dose accumulation information associated with the second location, second dose suggestion information associated with the second location and/or second patient outcomes information associated with the second location.
  • the second historical dose information may be indicative of one or more times of one or more second doses administered to the second location of the body and/or one or more dose parameters of the one or more second doses.
  • the second dose accumulation information may be indicative of a second dose accumulation level (e.g., a temporally corrected dose accumulation level) at the second location of the body.
  • a first dose accumulation model (e.g., a temporally corrected dose accumulation model) may be selected from a plurality of dose accumulation models (e.g., temporally corrected dose accumulation models) for use in generating the first patient profile 508.
  • the first dose accumulation model may be used to determine one, some and/or all dose accumulation levels of the first patient profile 508.
  • the first dose accumulation model may be selected (by a healthcare professional, for example) using a model selection interface 516.
  • a user may visualize differences between decay functions applied by different dose accumulation models of the plurality of dose accumulation models.
  • a dose accumulation model may be selected by a user (e.g., a healthcare professional) from among the plurality of dose accumulation models using the model selection window 518, and the user-selected dose accumulation model may be used to generate the first patient profile 508 in response to a selection of a generate profile selectable input 526.
  • the model selection interface 516 may display an indication 520 of the recommended dose accumulation model (and/or may highlight the recommended dose accumulation model).
  • the recommended dose accumulation model may be pre-selected in the model selection window 518 (prior to any selection by a user, for example).
  • the recommended dose accumulation model may be automatically selected and/or used to generate the first patient profile 508 without user intervention (e.g., the first dose accumulation model may be selected by the patient profile generation module 506 without user intervention).
  • the recommendation model may account for one or more sets of patient outcomes information (e.g., the first patient outcomes information, the second patient outcomes information, etc.) to select the recommended dose accumulation model.
  • the model visualization representation 522 (shown in Fig. 5B) may be indicative of the first dose accumulation level at the first location of the body.
  • the one or more first doses may comprise a dose (e.g., an initial dose of an initial treatment session) with a dose parameter corresponding to 60 gray (e.g., the dose of 60 gray may be administered to the first location of the body of the first patient at time 0.0 of the model visualization representation 522).
  • D t corresponds to a dose parameter (e.g., 60 gray) of a dose (e.g., initial dose)
  • t corresponds to time
  • a corresponds to a constant.
  • the first dose accumulation level over time determined using the exponential model may be represented by the third dose accumulation curve 524c of the model visualization representation 522.
  • D t corresponds to a dose parameter (e.g., 60 gray) of a dose (e.g., initial dose)
  • t corresponds to time
  • a and/or b correspond to constants.
  • the first dose accumulation level over time determined using the logarithmic model may be represented by the fourth dose accumulation curve 524d of the model visualization representation 522.
  • D t corresponds to a dose parameter (e.g., 60 gray) of a dose (e.g., initial dose)
  • t corresponds to time
  • a corresponds to a constant.
  • the first dose accumulation level over time determined using the Gaussian model may be represented by the first dose accumulation curve 524a of the model visualization representation 522.
  • the primate CNS model of the plurality of dose accumulation models determines a dose accumulation level of the first patient profile 508 by determining a tolerable dose parameter, and/or using the tolerable dose parameter to determine the dose accumulation level.
  • the tolerable dose parameter may correspond to a percentage of a maximum tolerable dose (e.g., a predefined value and/or a value determined based upon one or more reactions of the first patient to one or more treatment sessions, for example) that can be given to the first patient after a recovery period.
  • the maximum tolerable dose may be determined based upon patient outcomes information associated with the first patient.
  • the patient outcomes information may be analyzed to identify one or more negative reactions experienced and/or reported by the first user (e.g., symptoms, side effects, etc.).
  • the maximum tolerable dose may be determined based upon a dose accumulation level of the first patient at one or more times associated with the one or more negative reactions. Alternatively and/or additionally, the maximum tolerable dose may be determined based upon one or more historical doses administered to the first patient before the one or more negative reactions were experienced and/or reported.
  • the patient profile generation module 506 may use a dose decay function (e.g., a complex decay function) to determine a dose accumulation level (e.g., the first dose accumulation level) based upon patient outcomes information (e.g., the first patient outcomes information).
  • a dose decay function e.g., a complex decay function
  • the patient profile generation module 506 may comprise a trained dose accumulation determination model (e.g., a trained machine learning model for determining dose accumulation levels such as the first dose accumulation level based upon the records 502).
  • first training information for use in generating the trained dose accumulation determination model may be determined.
  • the first training information may comprise training records indicative of dose parameters associated with treatment sessions of one or more patients (e.g., the first patient and/or one or more other patients) and/or labels associated with the training sessions.
  • Each of the labels may be indicative of patient outcomes information associated with a corresponding treatment session (e.g., the patient outcomes information may be indicative of one or more symptoms of a patient, one or more side effects exhibited and/or reported by the patient, an intensity of side effects of the patient, one or more toxicity grades associated with one or more locations of the body of the patient, etc.), an outcome associated with the corresponding treatment session, one or more follow up tests associated with the corresponding treatment session, and/or other information associated with the corresponding treatment session.
  • a first machine learning model may be trained using the first training information to generate the trained dose accumulation determination model.
  • the recommendation model may comprise a trained recommendation determination model (e.g., a trained machine learning model for determining model recommendations such as the recommended dose accumulation model).
  • second training information for use in generating the trained recommendation determination model may be determined.
  • the second training information may comprise training records indicative of dose parameters associated with treatment sessions of one or more patients (e.g., the first patient and/or one or more other patients) and/or labels associated with the training sessions.
  • other dose accumulation levels of the first patient profile 508 may be determined using one or more of the techniques provided herein with respect to determining the first dose accumulation level.
  • the patient profile 508 may be indicative of various dose accumulation levels (e.g., temporally corrected radiation accumulation levels, temporally corrected chemotherapy accumulation levels, etc.) of various locations of the body.
  • the first patient profile 508 may be stored in a patient profile data store 512 (in response to generating the first patient profile 508, for example).
  • EHRs associated with patients may be stored in the patient profile data store 512.
  • the EHRs may comprise the first EHR associated with the first patient.
  • the first EHR may be supplemented with the first patient profile 508 (e.g., the first patient profile 508 may be included as part of the first EHR).
  • the first patient profile 508 may be linked to first EHR (e.g., the first patient profile 508 may comprise a link to access the first EHR and/or the first EHR may comprise a link to access the first patient profile 508).
  • the first patient profile 508 may be compatible with one or more standards (e.g., one or more medical imaging standards such as Digital Imaging and Communications in Medicine (DICOM) standard and/or one or more other standards).
  • DICOM Digital Imaging and Communications in Medicine
  • the first patient profile 508 may be used and/or accessed in various healthcare settings.
  • the patient profile data store 512 may provide healthcare professionals of different treatment areas and/or different healthcare settings with access to the first patient profile 508 (such that the healthcare professionals can use the first patient profile 508 for treating the first patient, for example).
  • the patient profile data store 512 may provide the first patient profile 508 (and/or a most recent version of the first patient profile 508) to the device in the first treatment setting.
  • the treatment planning and/or administration module 510 may provide the first patient profile 508 to the device for display.
  • the patient profile data store 512 may provide the first patient profile 508 to the device for display (in response to receiving a profile access request, for example).
  • Fig. 5C illustrates a device 571 displaying a patient profile interface 530 of the patient profile platform.
  • the patient profile interface 530 may display information of the first patient profile 508 and/or may provide one or more features to interact with information of the first patient profile 508, such as features to navigate through various information and/or representations associated with the first patient profile 508, and/or features to edit information of the first patient profile 508.
  • the patient profile interface 530 may comprise a patient information window 532 indicative of information associated with the first patient and/or one or more treatments of the first patient.
  • the patient profile interface 530 may comprise a dose volume histogram window 534 comprising a dose volume representation 552 associated with a location of the body of the first patient.
  • the location represented by the dose volume representation 552 e.g., a location corresponding to a lung of the first patient, a heart of the first patient, and/or one or more other organs of the first patient
  • the dose volume representation 552 may be indicative of a dose volume curve 536 that compares the volume of tissue of the location (e.g., lung tissue) with a range of radiation doses to which the tissue is exposed.
  • the patient profile interface 530 may comprise a cross section representation 544 comprising dose accumulation objects overlaid onto a cross sectional image associated with the first patient.
  • the dose accumulation objects may be indicative of dose accumulation levels at various locations of the body.
  • the dose accumulation objects may comprise a dose accumulation object 546a, a dose accumulation object 546b, a dose accumulation object 546c, a dose accumulation object 546d, a dose accumulation object 546e, a dose accumulation object 546f, a dose accumulation object 546g and/or a dose accumulation object 546h.
  • the dose accumulation objects may be visually representative of dose accumulation levels.
  • the dose accumulation objects may be color coded (in accordance with a color dose configuration 558, for example) such that a color of a dose accumulation object identifies a dose accumulation level associated with a corresponding location of the body (e.g., the corresponding location of the body may correspond to a portion of the cross sectional image that overlaps with, is adjacent to and/or is within a threshold distance of the dose accumulation object).
  • the dose accumulation objects may have different colors to identify different dose accumulation levels.
  • the patient profile interface 530 may comprise a body model avatar window 540 comprising an avatar representation 548 of the body model avatar and/or the color dose configuration 558.
  • the avatar representation 548 may be a three dimensional representation of dose accumulation levels at various locations of the body of the first patient.
  • colors of voxels of the body model avatar are selected according to the color dose configuration 558, which may identify color 560a for a dose accumulation level of 5 Gray, color 560b for a dose accumulation level of 10 Gray, color 560c for a dose accumulation level of 20 Gray, color 560d for a dose accumulation level of 40 Gray and/or color 560e for a dose accumulation level of 60 Gray.
  • the first location of the body of the first patient may be mapped to a first section 542a comprising one or more first voxels of the body model avatar, and/or a first color of the first section 542a may be selected based upon the first dose accumulation level associated with the first location (e.g., the one or more first voxels may be rendered in the first color in the avatar representation 548).
  • the patient profile interface 530 may comprise a dose accumulation over time representation 554 indicative of dose accumulation levels over time given different initial dose parameters.
  • the dose accumulation over time representation 554 may comprise a curve 556a indicative of dose accumulation levels over time given an initial dose parameter of 60 gray, a curve 556b indicative of dose accumulation levels over time given an initial dose parameter of 40 gray, a curve 556c indicative of dose accumulation levels over time given an initial dose parameter of 20 gray, a curve 556d indicative of dose accumulation levels over time given an initial dose parameter of 10 gray and/or a curve 556e indicative of dose accumulation levels over time given an initial dose parameter of 5 gray.
  • the patient profile interface 530 may comprise a second model selection window 562 indicative of the plurality of dose accumulation models.
  • the second model selection window 562 may be used to switch from using the first dose accumulation model to a different dose accumulation model of the plurality of dose accumulation models.
  • a set of dose accumulation levels may be determined using the different dose accumulation model.
  • the set of dose accumulation levels may be propagated to the patient profile interface 530, for example, by updating at least one of the dose volume representation 552, the avatar representation 548, the dose accumulation over time representation 554, etc. to be representative of the set of dose accumulation levels determined using the different dose accumulation model.
  • the treatment planning and/or administration module 510 may use the first patient profile 508 and/or one or more dose accumulation levels indicated by the first patient profile 508 to determine dose suggestion information indicative of a dose suggestion (e.g., a radiation dose suggestion, a chemotherapy dose suggestion, etc.) to administer to the first patient in a treatment session (e.g., a current and/or subsequent treatment session), such as a radiation therapy treatment session (e.g., radiation therapy treatment session for curative cancer application, non-curative cancer application, autoimmune disorder application, and/or one or more other applications), a chemotherapy treatment session, a cryoablation treatment session, a hyperthermia treatment session and/or a RFA treatment session.
  • a radiation therapy treatment session e.g., radiation therapy treatment session for curative cancer application, non-curative cancer application, autoimmune disorder application, and/or one or more other applications
  • a chemotherapy treatment session e.g., a cryoablation treatment session, a hyperthermia treatment session and/or a RFA treatment
  • the treatment planning and/or administration module 510 may provide the dose suggestion to a device for presentation (e.g., the dose suggestion may be displayed by the patient profile interface 530 and/or other interface of the patient profile platform). Alternatively and/or additionally, the treatment planning and/or administration module 510 may facilitate administration of the dose suggestion to the first patient. For example, the treatment planning and/or administration module 510 may transmit a message indicative of the dose suggestion to a tool that controls dosing of the treatment session (e.g., in response to receiving the message, the tool may control an amount of radiation delivered to the first patient in the treatment session based upon the dose suggestion).
  • the dose suggestion may be indicative of a target dose parameter tailored to the first patient for the treatment session (e.g., the current and/or subsequent treatment session) and/or a maximum tolerable dose parameter for the treatment session.
  • the treatment session may comprise a radiation therapy treatment session to administer radiation to the first patient
  • the target dose parameter may correspond to a suggested amount of radiation to be administered to the first patient in the treatment session
  • the maximum tolerable dose parameter may correspond to a maximum amount of radiation to be administered to the first patient (given a temporally corrected dose accumulation level, for example).
  • the treatment planning and/or administration module 510 may determine the first dose suggestion information indicative of a first dose suggestion (e.g., a radiation dose suggestion, a chemotherapy dose suggestion, etc.) associated with the first location.
  • a first dose suggestion e.g., a radiation dose suggestion, a chemotherapy dose suggestion, etc.
  • the first dose suggestion may be indicative of a first target dose parameter tailored to the first patient and/or the first location for a treatment session (e.g., a current and/or subsequent treatment session) and/or a first maximum tolerable dose parameter for the treatment session.
  • the treatment session may comprise a radiation therapy treatment session to administer radiation to the first location of the body of the first patient
  • the first target dose parameter may correspond to a suggested amount of radiation to be administered to the first location of the body of the first patient in the treatment session
  • the first maximum tolerable dose parameter may correspond to a maximum amount of radiation to be administered to the first location of the body of the first patient in the treatment session.
  • the first target dose parameter may be determined based upon the first dose accumulation level associated with the first location and/or treatment plan information associated with the first patient.
  • the treatment plan information may be indicative of one or more treatments (e.g., at least one of radiation therapy, chemotherapy, etc.) the first patient is currently undergoing and/or is planning to undergo.
  • the first maximum tolerable dose parameter may be determined based upon the first dose accumulation level associated with the first location and the maximum tolerable dose (and/or a location-specific maximum tolerable dose corresponding to the first location, for example). For example, the first maximum tolerable dose parameter may be about the maximum tolerable dose subtracted by the first dose accumulation level.
  • the treatment planning and/or administration module 510 may comprise a warning system that warns of and/or prevents administration of a dose that exceeds the first maximum tolerable dose parameter.
  • the patient profile interface 530 (and/or other interface of the patient profile platform) may display an interface to receive a planned dose to administer to the first location of the first patient in the treatment session.
  • the patient profile interface 530 (and/or other interface of the patient profile platform) may display an alert.
  • the treatment planning and/or administration module 510 may transmit a message indicative of the first dose suggestion to a tool that controls dosing of the treatment session.
  • the treatment session is a radiation therapy treatment session to administer radiation to the first location of the first patient
  • the tool may control an amount of the radiation delivered to the first patient in the treatment session based upon the first dose suggestion, such as by delivering radiation amounting to the first target dose parameter to the first location of the first patient.
  • the treatment planning and/or administration module 510 may determine the second dose suggestion information indicative of a second dose suggestion (e.g., a radiation dose suggestion, a chemotherapy dose suggestion, etc.) associated with the second location.
  • a second dose suggestion e.g., a radiation dose suggestion, a chemotherapy dose suggestion, etc.
  • the second dose suggestion may be indicative of a second target dose parameter tailored to the first patient and/or the second location for a treatment session (e.g., a current and/or subsequent treatment session) and/or a second maximum tolerable dose parameter for the treatment session.
  • the first patient profile 508 may be updated based upon one or more subsequent treatment sessions (and/or subsequent medical record entries).
  • the system 501 may detect and/or receive a record of a subsequent treatment session of the first patient.
  • the record may be indicative of a time of the subsequent treatment session, a dose parameter of a dose administered to the first patient in the subsequent treatment session, a type of treatment of the subsequent treatment session (e.g., radiation therapy, chemotherapy, etc.), a location to which the dose is administered, one or more side effects of the first patient, an intensity of side effects of the first patient, and/or other information.
  • the system 501 may update the first patient profile 508 based upon the record to generate an updated version of the first patient profile 508, and/or may store the updated version of the first patient profile 508 in the patient profile data store 512.
  • the updated version of the first patient profile 508 may be retrieved from the patient profile data store 512 and/or may be provide to a device (e.g., a device of the healthcare professional) for presentation, such as via the patient profile interface 530 (and/or other interfaces of the patient profile platform).
  • Figs. 5D-5H illustrate the patient profile interface 530 displayed at different times in a scenario in which the first patient undergoes radiation therapy treatment sessions.
  • the patient profile interface 530 may display a cross section representation 566 updated as of the corresponding time (e.g., the cross section representation 566 may have one or more of the features provided herein with respect to the cross section representation 544), an avatar representation 568 of the of the body model avatar updated as of the corresponding time (e.g., the avatar representation 568 may have one or more of the features provided herein with respect to the avatar representation 548) and/or a dose volume representation 570 (e.g., a dose volume histogram) updated as of the corresponding time.
  • a dose volume representation 570 e.g., a dose volume histogram
  • Fig. 5D illustrates the patient profile interface 530 displayed on a device 573 at a first time associated with an initial radiation therapy treatment session (e.g., the first time may be before, during or after the initial radiation therapy treatment session).
  • Fig. 5E illustrates the patient profile interface 530 displayed on a device 575 at a second time associated with a second radiation therapy treatment session after the initial radiation therapy treatment session (e.g., the second time may be before, during or after the second radiation therapy treatment session).
  • the second time may be about 188 days after the first time (and/or the second radiation therapy treatment session may be about 188 days after the initial radiation therapy treatment session).
  • Fig. 5D illustrates the patient profile interface 530 displayed on a device 573 at a first time associated with an initial radiation therapy treatment session (e.g., the first time may be before, during or after the initial radiation therapy treatment session).
  • Fig. 5E illustrates the patient profile interface 530 displayed on a device 575 at a second time associated with a second radiation therapy treatment
  • FIG. 5F illustrates the patient profile interface 530 displayed on a device 577 at a third time associated with a third radiation therapy treatment session after the second radiation therapy treatment session (e.g., the third time may be before, during or after the third radiation therapy treatment session).
  • the third time may be about 433 days after the second time (and/or the third radiation therapy treatment session may be about 433 days after the second radiation therapy treatment session).
  • Fig. 5G illustrates the patient profile interface 530 displayed on a device 579 at a fourth time associated with a fourth radiation therapy treatment session after the third radiation therapy treatment session (e.g., the fourth time may be before, during or after the fourth radiation therapy treatment session).
  • the fourth time may be about 100 days after the third time (and/or the fourth radiation therapy treatment session may be about 100 days after the third radiation therapy treatment session).
  • Fig. 5H illustrates the patient profile interface 530 displayed on a device 581 at a fifth time after the fourth radiation therapy treatment session.
  • the fifth time may be about 81 days after the fourth time.
  • some and/or all of devices 500, 571 , 573, 575, 577, 579 and/or 581 may be different devices.
  • some and/or all of devices 500, 571 , 573, 575, 577, 579 and/or 581 may be the same device.
  • the example method 600 includes collecting, at 602, collecting records (e.g., the records 502) of treatment sessions of a patient, wherein each of the records is indicative of a time of a treatment session and/or a dose parameter of a dose administered to the patient in the treatment session.
  • the example method 600 includes determining, at 604, a dose accumulation level (e.g., temporally corrected dose accumulation level) of the patient based upon times and dose parameters indicated by the records.
  • the dose accumulation level may be used to determine a radiation dose suggestion to administer to the patient, and/or may be used to generate a patient profile associated with the patient.
  • the treatment session includes a radiation therapy treatment session.
  • the computer-implemented method includes determining, based upon the dose accumulation level, a radiation dose suggestion to administer to the patient; and providing the radiation dose suggestion to a device for presentation, and/or facilitating administration of the radiation dose suggestion to the patient.
  • the dose accumulation level corresponds to a first location of a body of the patient
  • the computer- implemented method includes determining a second dose accumulation level corresponding to a second location of the body of the patient based upon the records; generating, based upon the dose accumulation level and the second dose accumulation level, a patient profile representative of dose accumulation levels at a plurality of locations of the body; and providing the patient profile to a device for presentation.
  • the patient profile includes a body model avatar displayed via a graphical user interface of the device.
  • the computer-implemented method includes mapping the first location of the body to one or more first voxels of the body model avatar; selecting a first color of the one or more first voxels based upon the dose accumulation level; mapping the second location of the body to one or more second voxels of the body model avatar; and selecting a second color of the one or more second voxels based upon the second dose accumulation level.
  • the computer-implemented method includes in response to generating the patient profile, storing the patient profile in a patient profile data store; receiving a record of a treatment session of the patient; updating the patient profile based upon the record to generate an updated patient profile; and storing the updated patient profile in the patient profile data store.
  • the computer-implemented method includes displaying a model selection interface indicative of a plurality of temporally corrected dose accumulation models; and receiving, via the model selection interface, a selection of a first temporally corrected dose accumulation model of the plurality of temporally corrected dose accumulation models, wherein determining the dose accumulation level is performed using the first temporally corrected dose accumulation model.
  • the treatment session includes a radiation therapy treatment session for a curative cancer application.
  • the treatment session includes a radiation therapy treatment session for a non-curative cancer application.
  • the treatment session includes a cryoablation treatment session.
  • the treatment session includes a RFA treatment session.
  • the dose records of the patient profile includes a first dose record mapped to a first location of the body, wherein the first dose record is indicative of one or more times of one or more doses administered to the first location of the body and one or more dose parameters of the one or more doses administered to the first location of the body; and a second dose record mapped to a second location of the body, wherein the second dose record is indicative of one or more times of one or more doses administered to the second location of the body and one or more dose parameters of the one or more doses administered to the first location of the body.
  • the patient profile includes a body model avatar displayed via a graphical user interface of the device.
  • a computing device includes a processor; and memory including processor-executable instructions that when executed by the processor cause performance of operations.
  • the operations include collecting records of treatment sessions of a patient, wherein each of the records is indicative of a time of a treatment session and a dose parameter of a dose administered to the patient in the treatment session; and determining, based upon times and dose parameters indicated by the records, a dose accumulation level of the patient.
  • the operations include determining, based upon the dose accumulation level, a treatment suggestion for the patient; and providing the treatment suggestion to a device for presentation and/or facilitating treatment of the patient according to the treatment suggestion.
  • a system including at least one aspect as described in the present disclosure and/or shown in the figures.
  • FIG. 7 is an illustration of a scenario 700 involving an example non-transitory machine readable medium 702.
  • the non-transitory machine readable medium 702 may comprise processor-executable instructions 712 that when executed by a processor 716 cause performance (e.g., by the processor 716) of at least some of the provisions herein (e.g., embodiment 714).
  • the non-transitory machine readable medium 702 may comprise a memory semiconductor (e.g., a semiconductor utilizing static random access memory (SRAM), dynamic random access memory (DRAM), and/or synchronous dynamic random access memory (SDRAM) technologies), a platter of a hard disk drive, a flash memory device, or a magnetic or optical disc (such as a compact disc (CD), digital versatile disc (DVD), or floppy disk).
  • a memory semiconductor e.g., a semiconductor utilizing static random access memory (SRAM), dynamic random access memory (DRAM), and/or synchronous dynamic random access memory (SDRAM) technologies
  • SSDRAM synchronous dynamic random access memory
  • the processor-executable instructions 712 when executed, cause performance of operations, such as at least some of the example method 400 of Fig. 4 and/or at least some of the example method 600 of Fig. 6, for example.
  • the processorexecutable instructions 712 are configured to cause implementation of a system, such as at least some of the example system 501 of Figs. 5A-5H, for example.
  • first,” “second,” and/or the like are not intended to imply a temporal aspect, a spatial aspect, an ordering, etc. Rather, such terms are merely used as identifiers, names, etc. for features, elements, items, etc.
  • a first object and a second object generally correspond to object A and object B or two different or two identical objects or the same object.
  • example is used herein to mean serving as an instance, illustration, etc., and not necessarily as advantageous.
  • “or” is intended to mean an inclusive “or” rather than an exclusive “or”.
  • “a” and “an” as used in this application are generally be construed to mean “one or more” unless specified otherwise or clear from context to be directed to a singular form.
  • at least one of A and B and/or the like generally means A or B or both A and B.
  • such terms are intended to be inclusive in a manner similar to the term “comprising”.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Business, Economics & Management (AREA)
  • General Business, Economics & Management (AREA)
  • Databases & Information Systems (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Treatment And Welfare Office Work (AREA)

Abstract

L'invention concerne un ou plusieurs dispositifs, systèmes et/ou procédés informatiques. Dans un exemple, des enregistrements de sessions de traitement d'un patient peuvent être collectés. Chacun des enregistrements peut indiquer un temps d'une session de traitement et un paramètre de dose d'une dose administrée au patient dans la session de traitement. Un niveau d'accumulation de dose du patient peut être déterminé sur la base de temps et de paramètres de dose indiqués par les enregistrements.
PCT/US2025/015919 2024-02-14 2025-02-14 Système et procédé de détermination d'accumulation de dose et de génération de profil de patient Pending WO2025175093A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202463553518P 2024-02-14 2024-02-14
US63/553,518 2024-02-14

Publications (1)

Publication Number Publication Date
WO2025175093A1 true WO2025175093A1 (fr) 2025-08-21

Family

ID=96773532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/015919 Pending WO2025175093A1 (fr) 2024-02-14 2025-02-14 Système et procédé de détermination d'accumulation de dose et de génération de profil de patient

Country Status (1)

Country Link
WO (1) WO2025175093A1 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110166410A1 (en) * 2008-06-25 2011-07-07 Koninklijke Philips Electronics N.V. Method and system for brachytherapy
US20150196267A1 (en) * 2012-11-15 2015-07-16 Kabushiki Kaisha Toshiba Exposure dose management system
US20150209566A1 (en) * 2002-02-14 2015-07-30 Gholam A. Peyman Method and composition for hyperthermally treating cells
US9764162B1 (en) * 2013-10-28 2017-09-19 Elekta, Inc. Automated, data-driven treatment management system for adaptive radiotherapy workflows
US20210304402A1 (en) * 2020-03-30 2021-09-30 Varian Medical Systems International Ag Systems and methods for pseudo image data augmentation for training machine learning models
US20220257978A1 (en) * 2021-02-16 2022-08-18 Siemens Healthcare Gmbh Radiation-Induced Toxicity and Machine Learning
US20230148984A1 (en) * 2021-02-24 2023-05-18 Shanghai United Imaging Healthcare Co., Ltd. Systems and methods for radiation dose management

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150209566A1 (en) * 2002-02-14 2015-07-30 Gholam A. Peyman Method and composition for hyperthermally treating cells
US20110166410A1 (en) * 2008-06-25 2011-07-07 Koninklijke Philips Electronics N.V. Method and system for brachytherapy
US20150196267A1 (en) * 2012-11-15 2015-07-16 Kabushiki Kaisha Toshiba Exposure dose management system
US9764162B1 (en) * 2013-10-28 2017-09-19 Elekta, Inc. Automated, data-driven treatment management system for adaptive radiotherapy workflows
US20210304402A1 (en) * 2020-03-30 2021-09-30 Varian Medical Systems International Ag Systems and methods for pseudo image data augmentation for training machine learning models
US20220257978A1 (en) * 2021-02-16 2022-08-18 Siemens Healthcare Gmbh Radiation-Induced Toxicity and Machine Learning
US20230148984A1 (en) * 2021-02-24 2023-05-18 Shanghai United Imaging Healthcare Co., Ltd. Systems and methods for radiation dose management

Similar Documents

Publication Publication Date Title
US12087453B2 (en) System and method for outcome tracking and analysis
JP6640913B2 (ja) エネルギーベース療法デバイスのパーソナライズされた画像ベースのガイダンス
US7606405B2 (en) Dynamic tumor diagnostic and treatment system
JP6530084B2 (ja) 再帰型ニューラルネットワークを使用する健康イベントの分析
JP6541868B2 (ja) 再帰型ニューラルネットワークを使用する、条件が満足される尤度の予測
JP6340059B2 (ja) アクセスコントロールを伴うクラウドベースの医療画像処理システム
US10872684B2 (en) System and method for medical data analysis and sharing
US11020613B2 (en) Physician directed radiation treatment planning
JP6097313B2 (ja) 匿名データをアップロード及びダウンロードするクラウドベースの医療画像処理システム
US20180122517A1 (en) Methods and apparatus related to electronic display of a human avatar with display properties particularized to health risks of a patient
CN102132280A (zh) 模型增强的成像
US11302440B2 (en) Accelerating human understanding of medical images by dynamic image alteration
EP3247463B1 (fr) Système et procédé pour options de classement pour traitements médicaux
CN113902642B (zh) 一种医学图像处理方法、装置、电子设备和存储介质
US20220414525A1 (en) Machine learning approach for solving beam angle optimization
CN102177519A (zh) 健康风险度量的确定和/或呈现
US20220398341A1 (en) Digital platform for community-based privacy-preserving data science
WO2009148803A2 (fr) Procédés et systèmes pour systèmes de santé intégrés
KR102323505B1 (ko) 반려 동물 관련 정보를 모듈화하여 유통시키는 방법 및 상기 방법을 실행시키기 위하여 컴퓨터 판독 가능한 저장 매체에 저장된 컴퓨터 프로그램
KR20200024374A (ko) 진료 매칭 방법 및 이를 수행하는 전자 장치
WO2025175093A1 (fr) Système et procédé de détermination d'accumulation de dose et de génération de profil de patient
US11515041B1 (en) Display of subset brain graph by shading nodes
US11540717B1 (en) Relative feature scores for brain parcels
US20240029888A1 (en) Generating and traversing data structures for automated classification
CN109121388B (zh) 定义与生物节律紊乱相关的旋转源的聚合稳定性图的方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25755709

Country of ref document: EP

Kind code of ref document: A1